Клинический разбор в общей медицине

В обзоре, подготовленном по выступлению профессора Е.В. Бирюковой «От данных к действию: оптимизация гликемического профиля и предотвращение осложнений посредством эффективного самоконтроля», рассмотрены эпидемиологическое бремя сахарного диабета, доказательная база необходимости проведения гликемического контроля, клиническое значение показателя гликированного гемоглобина (HbA1c), патофизиология гипогликемии и вариабельности гликемии, принципы структурированного самоконтроля глюкозы крови при сахарном диабете 1-го и 2-го типа (в том числе на фоне глюкокортикоидной терапии), а также инновационные возможности глюкометра Контур Плюс Элит с приложением Контур Диабитис.

Ключевые слова: сахарный диабет, самоконтроль гликемии, вариабельность гликемии, гипогликемия, глюкометр, цифровые технологии.

1. International Diabetes Federation. IDF Diabetes Atlas, 11th ed. 2025. URL: https://diabetesatlas.org

2. World Health Organization. Global status report on noncommunicable diseases. Geneva: WHO; 2011.

3. Zarich SW. Mechanism by which hyperglycemia plays a role in the setting of acute cardiovascular illness. Rev Cardiovasc Med 2006;7(Suppl.2):S35-43.

4. Bauters C Ennezat PV, Tricot O et al. REVE Investigators. Stress hyperglycaemia is an independent predictor of left ventricular remodelling after first anterior myocardial infarction in non-diabetic patients. Eur Heart J 2007;28:546-52. DOI: 10.1093/eurheartj/ehl546

5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, О.Ю. Сухаревой. 12-й выпуск (дополненный). М., 2025. 

6. Kalyani RR, Neumiller JJ, Maruthur NM, Wexler DJ. Diagnosis and treatment of type 2 diabetes in adults: A review. JAMA 2025;334:984-1002. DOI: 10.1001/jama.2025.5956

7. Bell DSH, McGill JB, Jerkins T. Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes. Diabetes Metab 2023;25(10):2795-2804. DOI: 10.1111/dom.15181.

8. Luca F et al. J Clin Med 2023;14(14):4834.

9. Amin-Salehi E, Letafatkar N, Norouzi N et al. Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries. Arch Med Res 2024;55(6):1030-4. DOI: 10.1016/j.arcmed.2024.103043

10. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86.

11. Nathan DM, and for the DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014;37:9-16.

12. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000;321(7258):405-12.

13. Sherwani SI, Khan HA, Ekhzaimy A et al. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights. 2016;11:95-104.

14. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44(Suppl.1):S73-S84.

15. Shepherd JG. South Med J. 2015;108(12):724-9.

16. Battelino T, Danne T, Bergenstal RM et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019;42(8):1593-603.

17. Zixin Chen et al. Non-glycemic factors affecting HbA1c. Exp Ther Med 2022;24(6):707.

18. March CA, Yates KA, Nougues LM et al. Awareness of hypoglycemia and its management in adults with type 1 diabetes. J Diabetes Complications 2017;31(3):577-82.

19. Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes. Diabetes Care 2003;26(4):1153-7.

20. J Diabetes Sci Technol 2015;9:668–75. BMJ Open Diabetes Research and Care 2017;5:e000342. URL: https://healthcare-in-europe.com/en/news/self-monitoring-of-blood-glucose.html

21. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25.

22. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354(9179):617-21. DOI: 10.1016/S0140-6736(98)12131-1. PMID: 10466661.

23. Shaw JE, Hodge AM, de Courten M et al. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999;42(9):1050-4. DOI: 10.1007/s001250051269. PMID: 10447514.

24. Tominaga M, Eguchi H, Manaka H et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22(6):920-4. DOI: 10.2337/diacare.22.6.920. PMID: 10372242

25. Balkau B, Shipley M, Jarrett RJ et al.High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21(3):360-7. DOI: 10.2337/diacare.21.3.360. PMID: 9540014.

26. Hanefeld M, Fischer S, Julius U et al.Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39(12):1577-83. DOI: 10.1007/s001250050617. PMID: 8960840.

27. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21(8):1236-9. DOI: 10.2337/diacare.21.8.1236. PMID: 9702431

28. Arreskov AB, Gazárek J, Böttcher M et al. Clinically meaningful corticosteroid-induced hyperglycaemia. BMC Endocr Disord 2019;19(1):60.

29. Klaff L, Bhargava A, Fusco-Walker S et al. Accuracy and user performance evaluation of a new, wireless-enabled blood glucose monitoring system. J Diabetes Sci Technol 2020;15(6):1382–1389. DOI: 10.1177/1932296820974348

30. Smartson online survey, Sweden 2017. 352 respondents with type 1 and type 2 diabetes. Survey funded by Ascensia Diabetes Care.

31. Grady M, Katz LB, Levy BL. Illuminated blood glucose meters may improve patient understanding of blood glucose levels and glycemic control. J Diabetes Sci Technol 2018;12(6):1211-19.

32. Richardson J et al. Clinical Relevance of Reapplication of Blood Samples During Blood Glucose Testing. Richardson J et al. Clinical Relevance of Reapplication of Blood Samples During Blood Glucose Testing. Poster presented at the virtual 20th Annual Diabetes Technology Meeting (DTM). 12 November 2020. Diabetes Technology Meeting Abstracts 2020; 15(2):A62. DOI: 10.1177/1932296821996093

33. Pardo S, Pardo S et al. Changes in Blood Glucose Excursions After at Least 180 Days Real-World Use of a New Smartphone Application. ATTD 2019; In: Diabetes Technology Meeting Abstracts 2018.